HRP20130861T1 - 1 h-benzimidazol-4-karboksamidi supstituirani s kvartarnim ugljikom na 2-položaju kao inhibitori parp-a za uporabu u lijeäśenju karcinoma - Google Patents
1 h-benzimidazol-4-karboksamidi supstituirani s kvartarnim ugljikom na 2-položaju kao inhibitori parp-a za uporabu u lijeäśenju karcinoma Download PDFInfo
- Publication number
- HRP20130861T1 HRP20130861T1 HRP20130861TT HRP20130861T HRP20130861T1 HR P20130861 T1 HRP20130861 T1 HR P20130861T1 HR P20130861T T HRP20130861T T HR P20130861TT HR P20130861 T HRP20130861 T HR P20130861T HR P20130861 T1 HRP20130861 T1 HR P20130861T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- nrcrd
- hydrogen
- group
- compound
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- JJDMKDXGNVJWCD-UHFFFAOYSA-N 1h-benzimidazole-4-carboxamide Chemical group NC(=O)C1=CC=CC2=C1N=CN2 JJDMKDXGNVJWCD-UHFFFAOYSA-N 0.000 title 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 238000011275 oncology therapy Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- JNAHVYVRKWKWKQ-UHFFFAOYSA-N 2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide Chemical compound N=1C2=C(C(N)=O)C=CC=C2NC=1C1(C)CCCN1 JNAHVYVRKWKWKQ-UHFFFAOYSA-N 0.000 claims 2
- JNAHVYVRKWKWKQ-ZDUSSCGKSA-N 2-[(2s)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide Chemical compound N=1C2=C(C(N)=O)C=CC=C2NC=1[C@]1(C)CCCN1 JNAHVYVRKWKWKQ-ZDUSSCGKSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
Claims (9)
1. Spoj Formule (I),
[image]
ili njegova terapijski prihvatljiva sol, za uporabu u liječenju raka kod sisavaca kod kojih je prepoznata potreba za takovim liječenjem, naznačen time, da
R1, R2, i R3 su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRARB i (NRARB)karbonila;
A je
[image]
R5 je neovisno odabran iz skupine koja se sastoji od alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, NRCRD i (NRCRD)karbonila; n je 0, 1, 2, or 3;
R6 je odabran iz skupine koja se sastoji od vodika, alkenila, alkoksialkila, alkoksikarbonila, alkoksikarbonilalkila, alkila, alkinila, arila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heterociklalkila, heteroarila, heteroarilalkila, hidroksialkila, (NRCRD)alkila, (NRCRD)karbonila, (NRCRD)karbonilalkila i (NRCRD)sulfonila;
Ra i Rb su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkilkarbonila; i
RC i Rd su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
2. Spoj za uporabu prema patentnom zahtjevu 1, naznačen time, da
R1, R2, i R3 su vodik; n je 0;
R6 je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRCRD)sulfonila; i
RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
3. Spoj za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da je spoj Formule (I)
2-(2-metilpirolidin-2-il)-1H-benzoimidazol-4-karboksamid;
2-[(2R)-2-metilpirolidin-2-il]-1H-benzoimidazol-4-karboksamid;
2-[(2S)-2-metilpirolidin-2-il]-1H-benzoimidazol-4-karboksamid;
ili njihova terapijski prihvatljiva sol.
4. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je rak leukemija, rak debelog crijeva, glioblastom, limfom, melanom, rak dojki ili rak grlića maternice.
5. Spoj Formule (I),
[image]
ili njegova terapijski prihvatljiva so, za uporabu kod potenciranja citotoksične terapije raka u sisavaca kod kojih je prepoznata potreba za takvim liječenjem, naznačen time, da
R1, R2, i R3 su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRaRb i (NRARB)karbonila;
A je
[image]
R5 je neovisno odabran iz skupine koja se sastoji od alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, NRCRD i (NRCRD)karbonila;
n je 0, 1, 2 ili 3;
R6 je odabran iz skupine koja se sastoji od vodika, alkenila, alkoksialkila, alkoksikarbonila, alkoksikarbonilalkila, alkila, alkinila, arila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heterociklalkila, heteroarila, heteroarilalkila, hidroksialkila, (NRCRD)alkila, (NRCRD)karbonila, (NRCRD)karbonilalkilalkila i (NRCRD)sulfonila;
RA i RB su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkilkarbonila; i
RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
6. Spoj za uporabu prema patentnom zahtjevu 5, naznačen time, da
R1, R2, i R3 su vodik;
n je 0;
R6 je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRCRD)sulfonila; i
RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
7. Spoj za uporabu prema patentnom zahtjevu 5 ili 6, naznačen time, da je spoj Formule (I)
2-(2-metilpirolidin-2-il)-1H-benzoimidazol-4-karboksamid;
2-[(2R)-2-metilpirolidin-2-il]-1H-benzoimidazol-4-karboksamid;
2-[(2S)-2-metilpirolidin-2-il]-1H-benzoimidazol-4-karboksamid;
ili njihova terapijski prihvatljiva sol.
8. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 5-7, naznačen time, da citotoksična terapija raka je zračenje.
9. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 5-7, naznačen time, da citotoksična terapija raka je kemoterapija.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67020405P | 2005-04-11 | 2005-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130861T1 true HRP20130861T1 (hr) | 2013-10-25 |
Family
ID=36940094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120819TT HRP20120819T1 (hr) | 2005-04-11 | 2012-10-11 | 1h-benzimidazol-4-karboksamidi supstituirani s kvaternarnim ugljikom na 2-položaju kao potentni parp inhibitori |
| HRP20130861TT HRP20130861T1 (hr) | 2005-04-11 | 2013-09-12 | 1 h-benzimidazol-4-karboksamidi supstituirani s kvartarnim ugljikom na 2-položaju kao inhibitori parp-a za uporabu u lijeäśenju karcinoma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120819TT HRP20120819T1 (hr) | 2005-04-11 | 2012-10-11 | 1h-benzimidazol-4-karboksamidi supstituirani s kvaternarnim ugljikom na 2-položaju kao potentni parp inhibitori |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7550603B2 (hr) |
| EP (3) | EP1869011B1 (hr) |
| JP (1) | JP4960342B2 (hr) |
| KR (1) | KR101349206B1 (hr) |
| CN (2) | CN104961723A (hr) |
| AU (1) | AU2006235492B2 (hr) |
| BR (1) | BRPI0609121B8 (hr) |
| CA (1) | CA2603784C (hr) |
| CY (1) | CY1123919T1 (hr) |
| DK (2) | DK1869011T3 (hr) |
| ES (2) | ES2426981T3 (hr) |
| HK (3) | HK1119168A1 (hr) |
| HR (2) | HRP20120819T1 (hr) |
| IL (2) | IL186303A (hr) |
| ME (2) | ME02087B (hr) |
| MX (1) | MX2007012593A (hr) |
| NZ (1) | NZ561729A (hr) |
| PL (2) | PL1869011T3 (hr) |
| PT (2) | PT2420234E (hr) |
| RS (2) | RS52990B (hr) |
| SI (1) | SI2420234T1 (hr) |
| TW (1) | TWI375673B (hr) |
| WO (1) | WO2006110816A2 (hr) |
| ZA (1) | ZA200904501B (hr) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010100977A (ko) | 1998-11-03 | 2001-11-14 | 스타르크, 카르크 | 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도 |
| FR2862971B1 (fr) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| WO2006110683A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| JP2008543786A (ja) * | 2005-06-10 | 2008-12-04 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ調節因子及び癌の治療 |
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| JP5227796B2 (ja) * | 2005-09-29 | 2013-07-03 | アボット・ラボラトリーズ | ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である |
| DE602006013191D1 (de) * | 2005-11-15 | 2010-05-06 | Abbott Lab | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
| US20080293795A1 (en) * | 2006-01-17 | 2008-11-27 | Abbott Laboratories | Combination therapy with parp inhibitors |
| US20090029966A1 (en) * | 2006-01-17 | 2009-01-29 | Abbott Laboratories | Combination therapy with parp inhibitors |
| WO2007084532A2 (en) * | 2006-01-17 | 2007-07-26 | Abbott Laboratories | Combination therapy with parp inhibitors |
| US20080146638A1 (en) * | 2006-01-17 | 2008-06-19 | Abbott Laboratories | Combination therapy with parp inhibitors |
| US20080280867A1 (en) * | 2006-01-17 | 2008-11-13 | Abbott Laboratories | Combination therapy with parp inhibitors |
| CA2647545C (en) * | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| CN101511821B (zh) * | 2006-05-02 | 2013-07-17 | Abbvie公司 | 取代的1h-苯并咪唑-4-羧酰胺类化合物是有效的parp抑制剂 |
| JP2010502731A (ja) | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法 |
| EP2059498A4 (en) | 2006-09-05 | 2011-01-12 | Bipar Sciences Inc | TREATMENT OF CANCER |
| US20100055071A1 (en) * | 2006-11-21 | 2010-03-04 | Martin Robert Leivers | Anti-Viral Compounds |
| RS58936B1 (sr) * | 2007-01-10 | 2019-08-30 | Msd Italia Srl | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| US8242303B2 (en) * | 2007-08-01 | 2012-08-14 | Nagase & Co., Ltd. | Method of producing optically active N-(halopropyl) amino acid derivative |
| US20090062268A1 (en) * | 2007-08-27 | 2009-03-05 | Lead Therapeutics, Inc. | Novel inhibitors of poly(adp-ribose)polymerase (parp) |
| CN101821269B (zh) * | 2007-10-12 | 2014-05-28 | 艾伯维巴哈马有限公司 | 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2 |
| BRPI0816221A8 (pt) | 2007-10-12 | 2015-09-22 | Abbott Lab | forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida |
| RU2480211C2 (ru) | 2007-11-12 | 2013-04-27 | Байпар Сайенсиз, Инк. | Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами |
| US8436185B2 (en) * | 2008-01-08 | 2013-05-07 | Merck Sharp & Dohme Corp. | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
| EP2247600A4 (en) * | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) |
| KR101007239B1 (ko) | 2008-08-20 | 2011-01-13 | 한국화학연구원 | 2-설파닐-벤즈이미다졸-4-카르복스아미드 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(ａｄｐ-리보스)폴리머라제-1(ｐａｒｐ-1)의 과활성에 의해 유발되는 질환의 예방 또는 치료용 약학적 조성물 |
| WO2010083199A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| TWI482621B (zh) | 2009-12-23 | 2015-05-01 | Sigma Tau Ind Farmaceuti | 青蒿素基藥物與其他化學治療劑的抗癌組合物 |
| HUP1000243A2 (en) | 2010-05-06 | 2012-01-30 | Avidin Kft | 8-hidroxy-quinoline derivatives |
| CA2798697A1 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| US20120258180A1 (en) * | 2011-04-11 | 2012-10-11 | Abbott Laboratories | Parp inhibitors for the treatment of cipn |
| JP5964297B2 (ja) | 2011-05-31 | 2016-08-03 | 株式会社エーピーアイ コーポレーション | 光学活性α−置換プロリン類の製造方法 |
| WO2013011999A1 (ja) | 2011-07-20 | 2013-01-24 | 株式会社カネカ | 光学活性２－メチルプロリン誘導体の製造法 |
| CA2873119A1 (en) | 2012-05-15 | 2013-11-21 | Abbvie Inc. | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US9346743B2 (en) | 2012-10-15 | 2016-05-24 | Albemarle Corporation | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds |
| WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
| EP3004086A1 (de) | 2013-06-03 | 2016-04-13 | Bayer Pharma Aktiengesellschaft | Substituierte benzoxazole |
| CN104230898B (zh) * | 2013-06-17 | 2016-06-29 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
| CN104230897B (zh) * | 2013-06-17 | 2016-07-06 | 上海汇伦生命科技有限公司 | 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途 |
| EP3079690A1 (en) | 2013-12-10 | 2016-10-19 | AbbVie Inc. | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer |
| CN104926793B (zh) * | 2014-03-21 | 2017-05-24 | 成都海创药业有限公司 | 一种治疗肿瘤的化合物及其用途 |
| MX2016016115A (es) | 2014-06-17 | 2017-03-08 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| CN106317069A (zh) * | 2015-06-26 | 2017-01-11 | 中国科学院上海药物研究所 | 2-取代苯并咪唑-4-甲酰胺类化合物及制备方法和应用 |
| ES2742197T7 (es) | 2015-07-23 | 2021-10-06 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| CN105130961B (zh) * | 2015-08-06 | 2018-02-16 | 苏州晶云药物科技有限公司 | Abt‑888的晶型b及其制备方法和应用 |
| CN106432195B (zh) * | 2015-08-12 | 2020-01-14 | 杭州民生药物研究院有限公司 | 一种制备(r)-2-(2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺的方法 |
| MX2018001659A (es) | 2015-08-20 | 2018-05-28 | Ipsen Biopharm Ltd | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. |
| PT3337478T (pt) | 2015-08-21 | 2020-10-19 | Ipsen Biopharm Ltd | Combinação de fármacos compreendendo irinotecano lipossómico, oxaliplatina, 5-fluorouracilo e leucovorina para o tratamento do cancro do pâncreas metastático |
| WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| CN106995436A (zh) * | 2016-01-25 | 2017-08-01 | 重庆医药工业研究院有限责任公司 | 一种维利帕尼晶型a及其制备方法 |
| US20190092756A1 (en) * | 2016-03-09 | 2019-03-28 | Crystal Pharmatech Co., Ltd. | Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof |
| IL261721B (en) | 2016-03-15 | 2022-07-01 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| CN107200704A (zh) * | 2016-03-18 | 2017-09-26 | 罗欣生物科技（上海）有限公司 | 一种维利帕尼的中间体晶体及其制备方法 |
| EP3275434B1 (en) | 2016-07-27 | 2020-08-26 | Sandoz Ag | An extended release oral dosage form |
| EA201990979A1 (ru) | 2016-11-02 | 2019-09-30 | Ипсен Биофарм Лтд. | Способы лечения рака желудочно-кишечного тракта с применением комбинационных видов терапии, содержащих липосомальный иринотекан и оксалиплатин |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| CN107098849B (zh) * | 2017-04-11 | 2019-09-20 | 山东百诺医药股份有限公司 | 一种盐酸左布比卡因的制备方法 |
| CN106866501B (zh) * | 2017-04-11 | 2019-09-20 | 山东百诺医药股份有限公司 | 一种盐酸左布比卡因的制备方法 |
| CA3021507A1 (en) | 2017-10-24 | 2019-04-24 | Apotex Inc. | Processes for the preparation of veliparib and intermediates thereof |
| CA3127990A1 (en) * | 2018-01-30 | 2019-08-08 | Board Of Regents, The University Of Texas System | Pipecolic esters for inhibition of the proteasome |
| JP7534218B2 (ja) | 2018-03-13 | 2024-08-14 | ヴァレリオ・セラピューティクス | がんの治療における獲得耐性に対抗するｄｂａｉｔ分子 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111471039B (zh) * | 2020-05-20 | 2023-07-25 | 上海腾卓药业有限责任公司 | 维利帕尼的制备方法 |
| WO2024057249A1 (en) * | 2022-09-14 | 2024-03-21 | Zydus Lifesciences Limited | Improved process for the preparation of sulfonylurea based compounds |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1021468B (de) * | 1954-09-15 | 1957-12-27 | Heinrich Hermanns | Traenkeinrichtung fuer elektrische Wicklungen, insbesondere fuer gewickelte Anker elektrischer Maschinen |
| GB1354554A (en) | 1970-08-31 | 1974-06-05 | Robins Co Inc A H | 2-substituted benzimidazoles |
| BE789679A (fr) | 1971-10-05 | 1973-04-04 | Leo Pharm Prod Ltd | Nouveaux derives d'acide amino-5 isophtalique et leurs procedesde preparation |
| US4093726A (en) | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
| DE3522230A1 (de) | 1985-06-21 | 1987-01-02 | Thomae Gmbh Dr K | Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JP2562953B2 (ja) * | 1988-09-02 | 1996-12-11 | シルバー株式会社 | 燃焼器具用芯の耐熱部材 |
| DE3830060A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| BR9610051A (pt) | 1995-08-02 | 1999-12-21 | Univ Newcastle Ventures Ltd | Uso de um composto, processo de preparação do mesmo, formulação ou composição farmacêutica contendo um composto, composição farmacêutica, e, processo de tratamento terapeutico |
| PT970095E (pt) | 1997-03-07 | 2004-03-31 | Metabasis Therapeutics Inc | Novos inibidores benzimidazole de frutose-1,6-bisfosfatase |
| US6911462B2 (en) | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| KR20010100977A (ko) | 1998-11-03 | 2001-11-14 | 스타르크, 카르크 | 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도 |
| KR20010080474A (ko) | 1998-11-17 | 2001-08-22 | 스타르크, 카르크 | 2-페닐벤즈이미다졸 및 2-페닐인돌, 이들의 제법 및 용도 |
| DE19916460B4 (de) | 1999-04-12 | 2006-12-21 | Abbott Gmbh & Co. Kg | Substituierte Benzimidazole, deren Herstellung und Anwendung |
| HUP0200749A3 (en) * | 1998-11-27 | 2003-03-28 | Basf Ag | Substituted benzimidazoles and their use as parp inhibitors and process for their preparation |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| EP1214330A1 (en) | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
| DE10021468A1 (de) | 2000-05-04 | 2001-11-08 | Basf Ag | Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen |
| JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
| US7166292B2 (en) | 2001-06-29 | 2007-01-23 | The Procter & Gamble Company | Top-biased beneficial components on substrates |
| AU2002334355A1 (en) | 2001-09-06 | 2003-03-18 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
| EP1511744A4 (en) | 2002-05-13 | 2009-10-21 | Icagen Inc | Bis-benzimidazoles and related compounds as potassium channel modulators |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| US20060084682A1 (en) | 2002-12-13 | 2006-04-20 | Heerding Dirk A | Thrombopoietin mimetics |
| US7179832B2 (en) | 2003-01-23 | 2007-02-20 | Crystalgenomics, Inc. | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof |
| HU0301154D0 (en) * | 2003-04-28 | 2003-07-28 | Hideg Kalman Dr | Pharmaceutical composition |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
-
2006
- 2006-04-10 TW TW095112748A patent/TWI375673B/zh active
- 2006-04-11 DK DK06749882.4T patent/DK1869011T3/da active
- 2006-04-11 RS RS20130428A patent/RS52990B/en unknown
- 2006-04-11 ME MEP-2013-428A patent/ME02087B/me unknown
- 2006-04-11 ME MEP-2012-464A patent/ME02027B/me unknown
- 2006-04-11 WO PCT/US2006/013652 patent/WO2006110816A2/en active Application Filing
- 2006-04-11 SI SI200631644T patent/SI2420234T1/sl unknown
- 2006-04-11 PL PL06749882T patent/PL1869011T3/pl unknown
- 2006-04-11 NZ NZ561729A patent/NZ561729A/en unknown
- 2006-04-11 JP JP2008506638A patent/JP4960342B2/ja active Active
- 2006-04-11 MX MX2007012593A patent/MX2007012593A/es active IP Right Grant
- 2006-04-11 AU AU2006235492A patent/AU2006235492B2/en active Active
- 2006-04-11 EP EP06749882A patent/EP1869011B1/en active Active
- 2006-04-11 CN CN201510145560.0A patent/CN104961723A/zh active Pending
- 2006-04-11 EP EP11189346.7A patent/EP2420234B1/en active Active
- 2006-04-11 BR BRPI0609121A patent/BRPI0609121B8/pt not_active IP Right Cessation
- 2006-04-11 EP EP11189349.1A patent/EP2420499B1/en active Active
- 2006-04-11 PT PT111893467T patent/PT2420234E/pt unknown
- 2006-04-11 PL PL11189346T patent/PL2420234T3/pl unknown
- 2006-04-11 CA CA2603784A patent/CA2603784C/en active Active
- 2006-04-11 KR KR1020077026128A patent/KR101349206B1/ko active IP Right Grant
- 2006-04-11 PT PT06749882T patent/PT1869011E/pt unknown
- 2006-04-11 DK DK11189346.7T patent/DK2420234T3/da active
- 2006-04-11 US US11/401,638 patent/US7550603B2/en active Active
- 2006-04-11 ES ES11189346T patent/ES2426981T3/es active Active
- 2006-04-11 ES ES06749882T patent/ES2391832T3/es active Active
- 2006-04-11 RS RS20120464A patent/RS52546B/en unknown
- 2006-04-11 CN CN200680011742.8A patent/CN101155797B/zh active Active
-
2007
- 2007-09-25 IL IL186303A patent/IL186303A/en active IP Right Grant
-
2008
- 2008-10-02 HK HK08111033.8A patent/HK1119168A1/xx unknown
-
2009
- 2009-06-26 ZA ZA200904501A patent/ZA200904501B/xx unknown
-
2012
- 2012-07-20 HK HK12107159.8A patent/HK1166465A1/xx unknown
- 2012-10-11 HR HRP20120819TT patent/HRP20120819T1/hr unknown
- 2012-10-19 CY CY20121100983T patent/CY1123919T1/el unknown
-
2013
- 2013-05-28 IL IL226619A patent/IL226619A/en active IP Right Grant
- 2013-09-12 HR HRP20130861TT patent/HRP20130861T1/hr unknown
-
2016
- 2016-04-01 HK HK16103730.1A patent/HK1215807A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130861T1 (hr) | 1 h-benzimidazol-4-karboksamidi supstituirani s kvartarnim ugljikom na 2-položaju kao inhibitori parp-a za uporabu u lijeäśenju karcinoma | |
| AR066104A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica | |
| ATE480239T1 (de) | Angiogeneseinhibitoren | |
| HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
| IL274936B2 (en) | Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors | |
| PE20091268A1 (es) | Derivados heterociclicos como inhibidores de pi3 quinasa | |
| ECSP088812A (es) | Derivados de dihidropirazolopirimidinona | |
| IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
| NZ597533A (en) | Apoptosis signal-regulating kinase inhibitors | |
| RU2017134379A (ru) | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 | |
| DK2080516T3 (da) | Anvendelse af isothiocyanatderivater som anti-myelom-midler | |
| SI2134691T1 (sl) | Derivati kvinolina kot PARP in TANK inhibitorji | |
| MX339668B (es) | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. | |
| ES2531256T3 (es) | Amidas fungicidas | |
| EA200800815A1 (ru) | 2-анилин-4-арилзамещенные тиазольные производные | |
| MX2007008308A (es) | Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-. | |
| RU2015131095A (ru) | Производные n-(замещенного)-5-фтор-4-имино-3-метил-2-оксо-3,4-дигидропиримидин-1(2н)-карбоксилата | |
| AR048195A1 (es) | Uso de un derivado de fenotiazina para la prevencion y/o tratamiento de la perdida de audicion | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| EA201190086A1 (ru) | Сочлененные производные имидазола в качестве антагониста trpv3 | |
| EA200700707A1 (ru) | Производные 2-ациламинотиазола | |
| NZ602883A (en) | Novel synthesis for thiazolidinedione compounds | |
| UA94053C2 (ru) | Замещенные производные 3-сульфонилиндазола в качестве лигандов гидрокситриптамина-6 | |
| ATE370955T1 (de) | N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden. |